• Skip to main content
  • Skip to footer

Delphi Diagnostics

Delphi Diagnostics guides personalized breast cancer therapy decisions with SET.

  • Our Technology
    • Lead Inventor
    • Breast Cancer Diagnostic Tests
    • Intellectual Property
  • Our Mission
  • Our Company
    • Board of Directors
    • Executive Team
    • Advisory Board
    • Trusted Collaborators
  • News
  • Contact Us
Home » News

News

Learn more about Delphi Diagnostics and the Sensitivity to Endocrine Therapy (SET2,3) Test by reading the latest news and press releases below.


Delphi Diagnostics™ Inc and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of Delphi’s Proprietary Test, SET2,3™, into the Adaptive Randomization Process for the Ongoing I-SPY 2 TRIAL™

October 27, 2022

Houston, TX, October 27th, 2022 – Delphi Diagnostics, Inc and Quantum Leap Healthcare Collaborative™ (QLHC) announce the inclusion of Delphi’s SET2,3TM test for use in the I-SPY 2 TRIAL for patients with locally advanced breast cancer. The SET2,3TM test helps to determine which patients with HR+ tumors will benefit from endocrine therapy., […]

Read More


Delphi DiagnosticsTM Inc. Announced the Issuance of a New U.S. Patent Covering the Sensitivity to Endocrine Therapy (SETER/PR) Test Through 2037

September 22, 2022

Patents recently issued in the US and allowed in Japan provide additional coverage for the company’s proprietary SETTM technologies for patients with HR+HER2- breast cancer and strengthens the company’s intellectual property portfolio., […]

Read More


SET2,3 Results Can Determine Prognosis and Prediction of Benefit from Dose-Dense Chemotherapy in Estrogen Receptor-Positive (ER+) Breast Cancer Presented at ASCO 2022

June 13, 2022

For patients diagnosed with ER+ breast cancer and low endocrine sensitivity (a Low SET2,3 index), dose-dense chemotherapy was associated with superior disease-free survival (DFS) and overall survival (OS) outcomes when compared to non-dose-dense regimens., […]

Read More


SET2,3 index adds independent, complementary information to personalize breast cancer treatment

December 14, 2021

Delphi Diagnostics Inc. is pleased to announce that its SET2,3 index, a standard measure of gene expression known as the Sensitivity-to-Endocrine-Therapy, was found to have prognostic value that complements the known prognostic value of the 21-gene Oncotype DX Recurrence Score in an analysis of data from postmenopausal patients with hormone receptor-positive breast cancer.[…]

Read More

Footer

Join us on:

  • LinkedIn
  • Privacy Policy
  • Contact Us
  • News

Copyright © 2023 · Delphi Diagnostics, Inc.™ All rights reserved.